Lupus nephritis: long-term follow-up.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D003165:Complement System Proteins / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D006801:Humans; D005779:Immunodiffusion; D007074:Immunoglobulin G / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009393:Nephritis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000401:mortality; D014168:Transferrin / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D007074:Immunoglobulin G; D014168:Transferrin; D003520:Cyclophosphamide; D003165:Complement System Proteins; D001379:Azathioprine